[Recommendations for management of dyslipidemia in 2014].
Benefit of statin treatment is well established for secondary prevention. For primary prevention, good data exist to support use of statins in high-risk groups. Less data are available for intermediate risk group and very few patients at low risk have been included in clinical trials. In this context, an individual approach based on a risk stratification using PROCAM score adjusted for Switzerland is recommended. Lifestyle measures should be tried first. We also discuss the new American guidelines and their related controversies. Secondary causes and familiar forms of dyslipidemias, for which a risk assessment cannot be performed using risk scores (first cardiovascular event between age 20 and 60), should not be overlooked.
M
M
Moser
B
B
Gencer
N
N
Rodondi
D002318:Cardiovascular Diseases / Q000517:prevention & control; D050171:Dyslipidemias / Q000145:classification / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors